

## Curriculum Vitae

▪ **Name** Chan Kim, MD, PhD

▪ **Address** Assistant Professor,  
Medical Oncology, Department of Internal Medicine,  
CHA Bundang Medical Center, CHA University,  
59 Yatap-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13496, Korea

### ▪ Education

1999.3.-2005.2. MD, Yonsei University College of Medicine, Seoul, Korea.  
2007.9.-2009.8. MS, Graduate School of Medicine, Yonsei University, Seoul, Korea.  
2010.2.-2013.2. PhD, Korea Advanced Institute of Science & Technology (KAIST), Daejeon, Korea.

### ▪ Professional Experiences

2005.3.-2006.2. Rotating internship, Severance Hospital, Yonsei University, Seoul, Korea  
2006.3.-2010.2. Residency, Severance Hospital, Yonsei University, Seoul, Korea  
2013.3.-2014.2. Postdoctoral Fellow, Laboratory of Vascular Biology and Stem Cells, KAIST  
2014.3.-2015.2. Clinical Fellow, Medical Oncology, Yonsei University, Seoul, Korea  
2015.3.-2015.8. Clinical Research Professor, Medical Oncology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea  
2015.9.- Assistant Professor, Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea

### ▪ Awards

1. Excellent Research Award, Korean Gastric Cancer Association, 2009
2. The 10<sup>th</sup> Academic Research Award, Korean Cancer Association and Sanofi-Aventis, 2010
3. The 24<sup>th</sup> Wunsch Medical Research Award, Korean Medical Research Association, 2014

### ▪ Selected list of Publications (\* as a co-first author)

1. Yang H, Lee WS, Kong SJ, Kim CG, Kim JH, Kim S, Kim G, Chon HJ, **Kim C.** STING Activation Reprograms Tumor Vasculatures and Synergizes with VEGFR2 Blockade. *Journal of Clinical*

**Investigation 2019** (IF 12.282);130 (**Corresponding author**)

2. **Kim C\***, Chon HJ\*, Kim JH, Jung M, Nam JM, Kim HS, Kang B, Chung HC, Rha SY. Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. **European Journal of Cancer 2019** (IF 7.191);112:20-28
3. Chon HJ, Lee WS, Yang H, Kong SJ, Lee NK, Moon ES, Choi J, Han EC, Kim JH, Ahn JB, Kim JH, **Kim C**. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade. **Clinical Cancer Research 2019** (IF 10.199);25(5):1612-1623 (**Selected as Cover Image**) (**Corresponding author**)
4. Chon HJ\*, **Kim C\***, Cho A, Kim YM, Jang SJ, Kim BO, Park CH, Hyung WJ, Ahn JB, Noh SH, Yun M, Rha SY. The Clinical Implications of FDG-PET/CT Differ According to Histology in Advanced Gastric Cancer. **Gastric Cancer 2018** (IF 5.454) (**\*Co-first author**)
5. **Kim C**, Kim WR, Kim KY, Chon H, Beom SH, Kim H, Jung M, Shin SJ, Kim N, Ahn JB. Predictive Nomogram for Recurrence of Stage I Colorectal Cancer Following Curative Resection. **Clinical Colorectal Cancer 2018** (IF 4.507);17(3):e513-e518.
6. Chon HJ, Hyung WJ, Kim C, Kim H, Park S, Park CH, Kim JH, Ahn JB, Chung HC, Rha SY, Noh SH, Jeung HC. Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis from a Single High-volume Center in Asia. **Annals of Surgery 2017** (IF 8.327), 265(5):946-953
7. Park JS, Kim IK, Han S, Park I, **Kim C**, Bae J, Oh SJ, Lee S, Kim JH, Woo DC, He Y, Augstin HG, Lee DH, Kim I, Koh GY. Normalization of Tumor Vasculature by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment. **Cancer Cell 2016** (IF 24.755), 30:953-967
8. **Kim C**, Kim EK, Jung H, Chon HJ, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Kim SH, Kim HS. Prognostic Implications of PD-L1 Expression in Patients with Soft Tissue Sarcoma. **BMC Cancer 2016** (IF 3.265), 16:434
9. **Kim C**, Yang H, Park I, Chon HJ, Kim JH, Kwon WS, Lee WS, Kim TS, Rha SY. Rho GTPase RhoJ is associated with gastric cancer progression and metastasis. **J Cancer 2016** (IF 3.609), 7(11):1550-1556
10. Kim Y, Nam HJ, Lee J, Park DY, **Kim C**, Yu YS, Kim D, Park SW, Bhin J, Hwang D, Lee H, Koh GY, Baik SH. Methylation-dependent Regulation of HIF-1 $\alpha$  Stability Restricts Retinal and Tumour Angiogenesis. **Nature Communications 2016** (IF 11.470), 7:10347
11. Lee JE\*, **Kim C\***, Yang H, Park I, Oh N, Kim H, Hua S, Jeong H, An HJ, Kim SC, Lee GM, Koh GY, Kim H. Novel Glycosylated VEGF Decoy Receptor, VEGF-Grab, Effectively Suppresses Tumor Angiogenesis and Progression. **Molecular Cancer Therapeutics 2015** (IF 6.107), 14(2):470-9 (**Selected as Highlight of issue**) (**\*Co-first author**).
12. **Kim C**, Yang H, Fukushima Y, Saw PE, Lee J, Park JS, Park I, Jung J, Kataoka H, Lee D, Heo WD, Kim I, Jon S, Adams RH, Nishikawa SI, Uemura A, Koh GY. Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption. **Cancer Cell 2014** (IF 24.755), 25(1):102-117 (**highlighted by SciBx & Faculty of 1000 Prime**)
13. Yang H\*, **Kim C\***, Kim MJ, Scwendener AR, Alitalo K, Heston W, Kim I, Kim WJ, Koh GY. Soluble Vascular Endothelial Growth Factor Receptor-3 Suppresses Lymphangiogenesis and Lymphatic Metastasis in Bladder Cancer. **Molecular Cancer 2011** (IF 5.397), 10:36. (**\*Co-first author**)

▪ **Patents**

US Patent: (14/271117), (14/740158), (9,505,841), (62647483), (PCT/US 2018/028952)